Celadon Pharmaceuticals (CEL) Competitors GBX 27.50 0.00 (0.00%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlines CEL vs. CNCT, CNSL, FOX, OTT, BCE, CZN, CHT, DVW, BRCI, and NPTShould you be buying Celadon Pharmaceuticals stock or one of its competitors? The main competitors of Celadon Pharmaceuticals include Smiths News Plc (CNCT.L) (CNCT), Cambridge Nutritional Sciences (CNSL), Fox Marble (FOX), Oxford Technology 3 Venture Capital Trust (OTT), Beacon Energy (BCE), Curzon Energy (CZN), 290005 (CHT.L) (CHT), 5008 (DVW.L) (DVW), BlackRock Comms Income Inv Tst (BRCI), and NetPlay TV (NPT). These companies are all part of the "communication" industry. Celadon Pharmaceuticals vs. Smiths News Plc (CNCT.L) Cambridge Nutritional Sciences Fox Marble Oxford Technology 3 Venture Capital Trust Beacon Energy Curzon Energy 290005 (CHT.L) 5008 (DVW.L) BlackRock Comms Income Inv Tst NetPlay TV Smiths News Plc (CNCT.L) (LON:CNCT) and Celadon Pharmaceuticals (LON:CEL) are both small-cap consumer cyclical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, community ranking, institutional ownership, risk and dividends. Do analysts recommend CNCT or CEL? Given Smiths News Plc (CNCT.L)'s higher possible upside, research analysts plainly believe Smiths News Plc (CNCT.L) is more favorable than Celadon Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Smiths News Plc (CNCT.L) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ACeladon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Is CNCT or CEL more profitable? Smiths News Plc (CNCT.L)'s return on equity of 0.00% beat Celadon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Smiths News Plc (CNCT.L)N/A N/A N/A Celadon Pharmaceuticals N/A -190.71%-34.40% Do insiders & institutionals have more ownership in CNCT or CEL? 10.7% of Celadon Pharmaceuticals shares are held by institutional investors. 65.1% of Celadon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has higher earnings & valuation, CNCT or CEL? Smiths News Plc (CNCT.L) has higher revenue and earnings than Celadon Pharmaceuticals. Celadon Pharmaceuticals is trading at a lower price-to-earnings ratio than Smiths News Plc (CNCT.L), indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSmiths News Plc (CNCT.L)£1.44B0.00N/A-£18.20N/ACeladon Pharmaceuticals£11.26K1,681.80-£5.23M-£0.08-343.75 Does the media prefer CNCT or CEL? In the previous week, Smiths News Plc (CNCT.L) had 2 more articles in the media than Celadon Pharmaceuticals. MarketBeat recorded 2 mentions for Smiths News Plc (CNCT.L) and 0 mentions for Celadon Pharmaceuticals. Smiths News Plc (CNCT.L)'s average media sentiment score of 0.31 beat Celadon Pharmaceuticals' score of 0.00 indicating that Smiths News Plc (CNCT.L) is being referred to more favorably in the media. Company Overall Sentiment Smiths News Plc (CNCT.L) Neutral Celadon Pharmaceuticals Neutral Does the MarketBeat Community favor CNCT or CEL? Smiths News Plc (CNCT.L) received 383 more outperform votes than Celadon Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Celadon Pharmaceuticals an outperform vote while only 75.00% of users gave Smiths News Plc (CNCT.L) an outperform vote. CompanyUnderperformOutperformSmiths News Plc (CNCT.L)Outperform Votes38775.00% Underperform Votes12925.00% Celadon PharmaceuticalsOutperform Votes4100.00% Underperform VotesNo Votes SummarySmiths News Plc (CNCT.L) beats Celadon Pharmaceuticals on 8 of the 12 factors compared between the two stocks. Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Get Celadon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CEL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CEL vs. The Competition Export to ExcelMetricCeladon PharmaceuticalsDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£18.93M£1.22B£5.39B£1.56BDividend YieldN/A3.13%5.13%11.24%P/E Ratio-343.75110.69114.371,707.53Price / Sales1,681.803,426.271,489.56226,865.74Price / Cash3.0510.1939.6735.60Price / Book6.883.174.662.85Net Income-£5.23M£155.16M£119.06M£144.51M7 Day Performance-6.78%-0.02%0.80%0.11%1 Month Performance-4.18%-0.71%5.65%-0.16%1 Year Performance-71.43%100.92%36.75%15.05% Celadon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELCeladon PharmaceuticalsN/AGBX 27.50flatN/A-72.0%£18.93M£11,258.00-343.752,780CNCTSmiths News Plc (CNCT.L)N/AGBX 25.60+1.6%N/AN/A£63.41M£1.44B-1.413News CoverageGap UpCNSLCambridge Nutritional SciencesN/AGBX 3.36+1.8%N/AN/A£8.00M£9.77M-362.103,200Gap DownFOXFox MarbleN/AGBX 1.35+14.9%N/A+0.0%£5.63M£722,064.00-135.0010,600OTTOxford Technology 3 Venture Capital TrustN/AGBX 34-19.4%N/AN/A£2.13M£-85,000.00-12.59203Gap DownBCEBeacon EnergyN/AGBX 0-20.0%N/A-97.3%£740,000.00N/A-0.3544,600Gap DownCZNCurzon EnergyN/AGBX 0.03flatN/A-95.6%£28,000.00N/A-2.8014,700News CoverageCHT290005 (CHT.L)N/AN/AN/AN/A£0.00N/A0.0020,300DVW5008 (DVW.L)N/AN/AN/AN/A£0.00N/A0.00N/AGap UpBRCIBlackRock Comms Income Inv TstN/AGBX 70.60-1.0%N/A+0.0%£0.00N/A0.00N/AHigh Trading VolumeNPTNetPlay TVN/AN/AN/AN/A£0.00N/A0.00147,000 Related Companies and Tools Related Companies Smiths News Plc (CNCT.L) Competitors Cambridge Nutritional Sciences Competitors Fox Marble Competitors Oxford Technology 3 Venture Capital Trust Competitors Beacon Energy Competitors Curzon Energy Competitors 290005 (CHT.L) Competitors 5008 (DVW.L) Competitors BlackRock Comms Income Inv Tst Competitors NetPlay TV Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:CEL) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celadon Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Celadon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
